Immusoft is developing a cutting edge approach to sustained delivery of protein therapeutics using a patient’s own cells. The approach is called Immune System Programming (ISP™). ISP entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce a given protein therapeutics.
Once we have programmed the B cells we expand the number of them many times and differentiate them into plasma cells (or, stated simply, coax them into the biofactory state) that produce massive amounts of our therapeutic protein. Thereafter we infuse the ISP™ programmed cells back into the same patient, where they take up residence and produce therapeutic proteins for extended periods of time.
This chart provides an overview of our ground breaking technology. Click below for a fuller explanation.
– Two presentations to highlight the transposon-engineered B lymphocytes ISP™ platform for MPS I and enhancement of muscle mass – Seattle, Wash.–(BUSINESS WIRE) –May 12, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced two upcoming virtual oral presentations at the ASGCT 23rd Annual…
– Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform – Seattle, Wash.–(BUSINESS WIRE) –February 5, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced that Scott McIvor, Ph.D., Chief Development Officer, and Professor Genetics, Cell Biology, and…
Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform